

Table 4.1 – Part 1 of 6

Outcomes of infants born in 2019 to persons infected with hepatitis B virus and managed by CDC Perinatal Hepatitis B Prevention Program through the end of 2020, 64 US Jurisdictions

Jurisdiction	All infants managed No.	HEPB VACCINE ADMINISTRATION	HEPB VACCINE ADMINISTRATION	HEPB VACCINE ADMINISTRATION	HEPB VACCINE ADMINISTRATION	POST VACCINATION SEROLOGIC TESTING	POST VACCINATION SEROLOGIC TESTING	POST VACCINATION SEROLOGIC TESTING
		HBIG & HepB at birth No. (%)	Complete series by 12 months of age No. (%)	Complete series after 12 months of age No. (%)	Total with complete series No. (%)	Received [†] No. (%)	HBsAg positive No. (%)	Immune [§] No. (%)
All Jurisdictions	9,055	8,709 (96%)	7,653 (85%)	131 (1%)	7,784 (86%)	5,759 (64%)	16 (0%)	5,523 (96%)
State								
Alabama	78	78 (100%)	30 (38%)	0 (0%)	30 (38%)	24 (31%)	0 (0%)	11 (46%)
Alaska	28	27 (96%)	25 (89%)	1 (4%)	26 (93%)	17 (61%)	0 (0%)	17 (100%)
Arizona	133	119 (89%)	103 (77%)	10 (8%)	113 (85%)	64 (48%)	0 (0%)	59 (92%)
Arkansas	61	60 (98%)	45 (74%)	0 (0%)	45 (74%)	40 (66%)	1 (3%)	37 (93%)
California	1,600	1,551 (97%)	1,204 (75%)	6 (0%)	1,210 (76%)	908 (57%)	2 (0%)	866 (95%)
Colorado	111	111 (100%)	108 (97%)	1 (1%)	109 (98%)	100 (90%)	0 (0%)	99 (99%)
Connecticut	40	38 (95%)	1 (3%)	1 (3%)	2 (5%)	1 (3%)	0 (0%)	1 (100%)
Delaware	45	45 (100%)	26 (58%)	12 (27%)	38 (84%)	38 (84%)	0 (0%)	34 (89%)
Florida	394	347 (88%)	298 (76%)	2 (1%)	300 (76%)	96 (24%)	0 (0%)	90 (94%)
Georgia	283	270 (95%)	258 (91%)	2 (1%)	260 (92%)	230 (81%)	1 (0%)	222 (97%)
Hawaii	139	137 (99%)	131 (94%)	2 (1%)	133 (96%)	114 (82%)	0 (0%)	113 (99%)

HBIG=hepatitis B immune globulin; HepB=hepatitis B vaccine; HBsAg=hepatitis B surface antigen; anti-HBs= antibody to hepatitis B surface antigen; U= The data were unavailable

* These data only include infants followed by the PHBPP. National and jurisdictional level HepB vaccination coverage rates are available via annual MMWR publications of National Immunization Survey data (<https://www.cdc.gov/vaccines/imz-managers/nis/index.html>) and via VaxView (<https://www.cdc.gov/vaccines/vaxview/index.html>).

† Post vaccination serologic testing includes a test for HBsAg, anti-HBs, or both. Results from post vaccination serologic testing may be reported as HBsAg positive, HBsAg negative and immune or not immune, or indeterminate.

§ Anti-HBs >10 mIU/mL

¶ Percentage is among infants that completed the vaccine series and received PVST.

** City data are mutually exclusive from state data.

Source: CDC, National Notifiable Diseases Surveillance System.

Centers for Disease Control and Prevention. Viral Hepatitis Surveillance Report – United States, 2020. <https://www.cdc.gov/hepatitis/statistics/2020surveillance/index.htm>. Published September 2022.



Table 4.1 – Part 2 of 6

Outcomes of infants born in 2019 to persons infected with hepatitis B virus and managed by CDC Perinatal Hepatitis B Prevention Program through the end of 2020, 64 US Jurisdictions

Jurisdiction State	All infants managed No.	HEPB VACCINE ADMINISTRATION	HEPB VACCINE ADMINISTRATION	HEPB VACCINE ADMINISTRATION	HEPB VACCINE ADMINISTRATION	POST VACCINATION SEROLOGIC TESTING	POST VACCINATION SEROLOGIC TESTING	POST VACCINATION SEROLOGIC TESTING
		HBIG & HepB at birth No. (%)	Complete series by 12 months of age No. (%)	Complete series after 12 months of age No. (%)	Total with complete series No. (%)	Received [†] No. (%)	HBsAg positive No. (%)	Immune [§] No. (%)
Idaho	17	16 (94%)	16 (94%)	0 (0%)	16 (94%)	11 (65%)	0 (0%)	11 (100%)
Illinois	162	160 (99%)	144 (89%)	1 (1%)	145 (90%)	99 (61%)	0 (0%)	92 (93%)
Indiana	117	117 (100%)	113 (97%)	0 (0%)	113 (97%)	86 (74%)	1 (1%)	85 (99%)
Iowa	121	119 (98%)	111 (92%)	0 (0%)	111 (92%)	73 (60%)	0 (0%)	68 (93%)
Kansas	44	43 (98%)	39 (89%)	1 (2%)	40 (91%)	27 (61%)	0 (0%)	19 (70%)
Kentucky	60	55 (92%)	48 (80%)	2 (3%)	50 (83%)	30 (50%)	0 (0%)	29 (97%)
Louisiana	123	108 (88%)	103 (84%)	5 (4%)	108 (88%)	63 (51%)	2 (3%)	57 (90%)
Maine	10	10 (100%)	10 (100%)	0 (0%)	10 (100%)	7 (70%)	0 (0%)	7 (100%)
Maryland	253	239 (94%)	210 (83%)	7 (3%)	217 (86%)	158 (62%)	0 (0%)	151 (96%)
Massachusetts	307	303 (99%)	291 (95%)	0 (0%)	291 (95%)	271 (88%)	0 (0%)	265 (98%)
Michigan	152	152 (100%)	140 (92%)	2 (1%)	142 (93%)	121 (80%)	0 (0%)	118 (98%)
Minnesota	398	395 (99%)	376 (94%)	5 (1%)	381 (96%)	304 (76%)	0 (0%)	298 (98%)
Mississippi	54	51 (94%)	41 (76%)	1 (2%)	42 (78%)	31 (57%)	0 (0%)	29 (94%)
Missouri	84	81 (96%)	72 (86%)	1 (1%)	73 (87%)	48 (57%)	0 (0%)	43 (90%)

§ Anti-HBs >10 mIU/mL

¶ Percentage is among infants that completed the vaccine series and received PVST.

** City data are mutually exclusive from state data.

Source: CDC, National Notifiable Diseases Surveillance System.

Centers for Disease Control and Prevention. Viral Hepatitis Surveillance Report – United States, 2020. <https://www.cdc.gov/hepatitis/statistics/2020surveillance/index.htm>. Published September 2022.

HBIG=hepatitis B immune globulin; HepB=hepatitis B vaccine; HBsAg=hepatitis B surface antigen; anti-HBs= antibody to hepatitis B surface antigen; U= The data were unavailable

* These data only include infants followed by the PHBPP. National and jurisdictional level HepB vaccination coverage rates are available via annual MMWR publications of National Immunization Survey data (<https://www.cdc.gov/vaccines/imz-managers/nis/index.html>) and via VaxView (<https://www.cdc.gov/vaccines/vaxview/index.html>).

† Post vaccination serologic testing includes a test for HBsAg, anti-HBs, or both. Results from post vaccination serologic testing may be reported as HBsAg positive, HBsAg negative and immune or not immune, or indeterminate.



Table 4.1 – Part 3 of 6

Outcomes of infants born in 2019 to persons infected with hepatitis B virus and managed by CDC Perinatal Hepatitis B Prevention Program through the end of 2020, 64 US Jurisdictions

Jurisdiction State	All infants managed No.	HEPB VACCINE ADMINISTRATION	HEPB VACCINE ADMINISTRATION	HEPB VACCINE ADMINISTRATION	HEPB VACCINE ADMINISTRATION	POST VACCINATION SEROLOGIC TESTING	POST VACCINATION SEROLOGIC TESTING	POST VACCINATION SEROLOGIC TESTING
		HBIG & HepB at birth No. (%)	Complete series by 12 months of age No. (%)	Complete series after 12 months of age No. (%)	Total with complete series No. (%)	Received [†] No. (%)	HBsAg positive No. (%)	Immune [§] No. (%)
Montana	10	9 (90%)	6 (60%)	0 (0%)	6 (60%)	4 (40%)	0 (0%)	4 (100%)
Nebraska	62	43 (69%)	56 (90%)	0 (0%)	56 (90%)	44 (71%)	0 (0%)	42 (95%)
Nevada	82	82 (100%)	81 (99%)	0 (0%)	81 (99%)	59 (72%)	0 (0%)	58 (98%)
New Hampshire	16	16 (100%)	10 (63%)	0 (0%)	10 (63%)	7 (44%)	0 (0%)	7 (100%)
New Jersey	271	244 (90%)	196 (72%)	10 (4%)	206 (76%)	98 (36%)	0 (0%)	88 (90%)
New Mexico	11	9 (82%)	10 (91%)	1 (9%)	11 (100%)	9 (82%)	0 (0%)	7 (78%)
New York State	218	205 (94%)	201 (92%)	1 (0%)	202 (93%)	166 (76%)	0 (0%)	163 (98%)
North Carolina	191	184 (96%)	174 (91%)	4 (2%)	178 (93%)	122 (64%)	0 (0%)	119 (98%)
North Dakota	36	35 (97%)	27 (75%)	5 (14%)	32 (89%)	15 (42%)	0 (0%)	15 (100%)
Ohio	269	264 (98%)	223 (83%)	2 (1%)	225 (84%)	113 (42%)	2 (2%)	102 (90%)
Oklahoma	69	67 (97%)	61 (88%)	2 (3%)	63 (91%)	46 (67%)	0 (0%)	45 (98%)
Oregon	50	40 (80%)	39 (78%)	4 (8%)	43 (86%)	0 (0%)	0 (0%)	0 (0%)
Pennsylvania	191	189 (99%)	171 (90%)	4 (2%)	175 (92%)	113 (59%)	0 (0%)	112 (99%)

HBIG=hepatitis B immune globulin; HepB=hepatitis B vaccine; HBsAg=hepatitis B surface antigen; anti-HBs= antibody to hepatitis B surface antigen; U= The data were unavailable

* These data only include infants followed by the PHBPP. National and jurisdictional level HepB vaccination coverage rates are available via annual MMWR publications of National Immunization Survey data (<https://www.cdc.gov/vaccines/imz-managers/nis/index.html>) and via VaxView (<https://www.cdc.gov/vaccines/vaxview/index.html>).

† Post vaccination serologic testing includes a test for HBsAg, anti-HBs, or both. Results from post vaccination serologic testing may be reported as HBsAg positive, HBsAg negative and immune or not immune, or indeterminate.

§ Anti-HBs >10 mIU/mL

¶ Percentage is among infants that completed the vaccine series and received PVST.

** City data are mutually exclusive from state data.

Source: CDC, National Notifiable Diseases Surveillance System.

Centers for Disease Control and Prevention. Viral Hepatitis Surveillance Report – United States, 2020. <https://www.cdc.gov/hepatitis/statistics/2020surveillance/index.htm>. Published September 2022.



Table 4.1 – Part 4 of 6

Outcomes of infants born in 2019 to persons infected with hepatitis B virus and managed by CDC Perinatal Hepatitis B Prevention Program through the end of 2020, 64 US Jurisdictions

Jurisdiction	All infants managed No.	HEPB VACCINE ADMINISTRATION	HEPB VACCINE ADMINISTRATION	HEPB VACCINE ADMINISTRATION	HEPB VACCINE ADMINISTRATION	POST VACCINATION SEROLOGIC TESTING	POST VACCINATION SEROLOGIC TESTING	POST VACCINATION SEROLOGIC TESTING
		HBIG & HepB at birth No. (%)	Complete series by 12 months of age No. (%)	Complete series after 12 months of age No. (%)	Total with complete series No. (%)	Received [†] No. (%)	HBsAg positive No. (%)	Immune [§] No. (%)
State								
Rhode Island	35	35 (100%)	33 (94%)	0 (0%)	33 (94%)	27 (77%)	0 (0%)	25 (93%)
South Carolina	64	59 (92%)	51 (80%)	1 (2%)	52 (81%)	36 (56%)	0 (0%)	36 (100%)
South Dakota	16	16 (100%)	16 (100%)	0 (0%)	16 (100%)	10 (63%)	0 (0%)	10 (100%)
Tennessee	117	113 (97%)	113 (97%)	2 (2%)	115 (98%)	78 (67%)	0 (0%)	74 (95%)
Texas	539	519 (96%)	462 (86%)	2 (0%)	464 (86%)	377 (70%)	0 (0%)	363 (96%)
Utah	77	76 (99%)	71 (92%)	1 (1%)	72 (94%)	43 (56%)	0 (0%)	43 (100%)
Vermont	5	5 (100%)	5 (100%)	0 (0%)	5 (100%)	1 (20%)	0 (0%)	0 (0%)
Virginia	243	229 (94%)	228 (94%)	2 (1%)	230 (95%)	146 (60%)	0 (0%)	141 (97%)
Washington	U	U (U)	U (U)	U (U)	U (U)	U (U)	U (U)	U (U)
West Virginia	21	21 (100%)	21 (100%)	0 (0%)	21 (100%)	19 (90%)	0 (0%)	19 (100%)
Wisconsin	142	142 (100%)	131 (92%)	3 (2%)	134 (94%)	95 (67%)	2 (2%)	92 (97%)
Wyoming	3	3 (100%)	2 (67%)	1 (33%)	3 (100%)	1 (33%)	0 (0%)	1 (100%)

HBIG=hepatitis B immune globulin; HepB=hepatitis B vaccine; HBsAg=hepatitis B surface antigen; anti-HBs= antibody to hepatitis B surface antigen; U= The data were unavailable

* These data only include infants followed by the PHBPP. National and jurisdictional level HepB vaccination coverage rates are available via annual MMWR publications of National Immunization Survey data (<https://www.cdc.gov/vaccines/imz-managers/nis/index.html>) and via VaxView (<https://www.cdc.gov/vaccines/vaxview/index.html>).

† Post vaccination serologic testing includes a test for HBsAg, anti-HBs, or both. Results from post vaccination serologic testing may be reported as HBsAg positive, HBsAg negative and immune or not immune, or indeterminate.

§ Anti-HBs >10 mIU/mL

¶ Percentage is among infants that completed the vaccine series and received PVST.

** City data are mutually exclusive from state data.

Source: CDC, National Notifiable Diseases Surveillance System.

Centers for Disease Control and Prevention. Viral Hepatitis Surveillance Report – United States, 2020. <https://www.cdc.gov/hepatitis/statistics/2020surveillance/index.htm>. Published September 2022.



Table 4.1 – Part 5 of 6

Outcomes of infants born in 2019 to persons infected with hepatitis B virus and managed by CDC Perinatal Hepatitis B Prevention Program through the end of 2020, 64 US Jurisdictions

Jurisdiction City**	All infants managed No.	HEPB VACCINE ADMINISTRATION	HEPB VACCINE ADMINISTRATION	HEPB VACCINE ADMINISTRATION	HEPB VACCINE ADMINISTRATION	POST VACCINATION SEROLOGIC TESTING	POST VACCINATION SEROLOGIC TESTING	POST VACCINATION SEROLOGIC TESTING
		HBIG & HepB at birth No. (%)	Complete series by 12 months of age No. (%)	Complete series after 12 months of age No. (%)	Total with complete series No. (%)	Received [†] No. (%)	HBsAg positive No. (%)	Immune [§] No. (%)
Chicago	102	101 (99%)	78 (76%)	0 (0%)	78 (76%)	70 (69%)	0 (0%)	69 (99%)
District of Columbia	27	27 (100%)	25 (93%)	0 (0%)	25 (93%)	22 (81%)	0 (0%)	22 (100%)
Houston	119	113 (95%)	98 (82%)	4 (3%)	102 (86%)	87 (73%)	0 (0%)	85 (98%)
New York City	1,031	1,028 (100%)	949 (92%)	5 (0%)	954 (93%)	875 (85%)	0 (0%)	856 (98%)
Philadelphia	128	111 (87%)	103 (80%)	7 (5%)	110 (86%)	84 (66%)	0 (0%)	78 (93%)
San Antonio	36	36 (100%)	30 (83%)	2 (6%)	32 (89%)	25 (69%)	0 (0%)	25 (100%)
Territory								
American Samoa	3	3 (100%)	3 (100%)	0 (0%)	3 (100%)	0 (0%)	0 (0%)	0 (0%)
Guam	12	12 (100%)	3 (25%)	4 (33%)	7 (58%)	0 (0%)	0 (0%)	0 (0%)
N. Mariana Islands	5	5 (100%)	5 (100%)	0 (0%)	5 (100%)	5 (100%)	5 (100%)	0 (0%)
Puerto Rico	1	1 (100%)	1 (100%)	0 (0%)	1 (100%)	0 (0%)	0 (0%)	0 (0%)
Virgin Islands	1	1 (100%)	1 (100%)	0 (0%)	1 (100%)	1 (100%)	0 (0%)	1 (100%)

HBIG=hepatitis B immune globulin; HepB=hepatitis B vaccine; HBsAg=hepatitis B surface antigen; anti-HBs= antibody to hepatitis B surface antigen; U= The data were unavailable

§ Anti-HBs >10 mIU/mL

¶ Percentage is among infants that completed the vaccine series and received PVST.

* These data only include infants followed by the PHBPP. National and jurisdictional level HepB vaccination coverage rates are available via annual MMWR publications of National Immunization Survey data (<https://www.cdc.gov/vaccines/imz-managers/nis/index.html>) and via VaxView (<https://www.cdc.gov/vaccines/vaxview/index.html>).

** City data are mutually exclusive from state data.

Source: CDC, National Notifiable Diseases Surveillance System.

† Post vaccination serologic testing includes a test for HBsAg, anti-HBs, or both. Results from post vaccination serologic testing may be reported as HBsAg positive, HBsAg negative and immune or not immune, or indeterminate.

Centers for Disease Control and Prevention. Viral Hepatitis Surveillance Report – United States, 2020. <https://www.cdc.gov/hepatitis/statistics/2020surveillance/index.htm>. Published September 2022.



Table 4.1 – Part 6 of 6

Outcomes of infants born in 2019 to persons infected with hepatitis B virus and managed by CDC Perinatal Hepatitis B Prevention Program through the end of 2020, 64 US Jurisdictions

Jurisdiction	All infants managed No.	HEPB VACCINE ADMINISTRATION	HEPB VACCINE ADMINISTRATION	HEPB VACCINE ADMINISTRATION	HEPB VACCINE ADMINISTRATION	POST VACCINATION SEROLOGIC TESTING	POST VACCINATION SEROLOGIC TESTING	POST VACCINATION SEROLOGIC TESTING
		HBIG & HepB at birth No. (%)	Complete series by 12 months of age No. (%)	Complete series after 12 months of age No. (%)	Total with complete series No. (%)	Received [†] No. (%)	HBsAg positive No. (%)	Immune [§] No. (%)
Freely Associated Island Nations								
Marshall Islands	U	U (U)	U (U)	U (U)	U (U)	U (U)	U (U)	U (U)
Micronesia	35	32 (91%)	23 (66%)	2 (6%)	25 (71%)	0 (0%)	0 (0%)	0 (0%)
Palau	3	2 (67%)	3 (100%)	0 (0%)	3 (100%)	0 (0%)	0 (0%)	0 (0%)

HBIG=hepatitis B immune globulin; HepB=hepatitis B vaccine; HBsAg=hepatitis B surface antigen; anti-HBs= antibody to hepatitis B surface antigen; U= The data were unavailable

* These data only include infants followed by the PHBPP. National and jurisdictional level HepB vaccination coverage rates are available via annual MMWR publications of National Immunization Survey data (<https://www.cdc.gov/vaccines/imz-managers/nis/index.html>) and via VaxView (<https://www.cdc.gov/vaccines/vaxview/index.html>).

† Post vaccination serologic testing includes a test for HBsAg, anti-HBs, or both. Results from post vaccination serologic testing may be reported as HBsAg positive, HBsAg negative and immune or not immune, or indeterminate.

§ Anti-HBs >10 mIU/mL

¶ Percentage is among infants that completed the vaccine series and received PVST.

** City data are mutually exclusive from state data.

Source: CDC, National Notifiable Diseases Surveillance System.

Centers for Disease Control and Prevention. Viral Hepatitis Surveillance Report – United States, 2020. <https://www.cdc.gov/hepatitis/statistics/2020surveillance/index.htm>. Published September 2022.

